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PDII-A-3 
EFFECTS OF RIFAMPIN ON THE PHARMACOKINETICS 
AND PHARMACODYNAMICS OF GLICLAZIDE. J. Park, MD, 
K. Kim, PhD, J. Shin, MD, PhD, Gachon Medical School, Kyung- 
Hee University, Inje University, Incheon, Korea. 
Objective: Rifampin is a potent inducer of several cytochrome 
P450 (CYP) enzymes. Gliclazide is a sulfonylurea antidiabetic drug, 
suggested to be metabolized by CYP2C9. Our aim of this study was 
to evaluate the effect of rifampin on the pharmacokinetics and phar- 
macodynamics of gliclazide. 
Method: In a randomized, two-phase crossover study, 9 healthy 
subjects were treated for 6 days with 600 mg rifampin or placebo 
once daily. On day 6, a single oral dose of 80 mg gliclazide was 
administered. Plasma gliclazide and blood glucose concentrations 
were measured. 
Results: Rifampin decreased the mean area under the plasma 
concentration-time curve of gliclazide by 69.8 % (p<.001) and the 
mean elimination half-life from 9.5 to 3.3 hours (p<.05). The clear- 
ance of gliclazide increased about 4-fold after rifampin treatment 
(p<.001). Significant difference in the blood glucose response to 
gliclazide was observed between placebo and rifampin phase. 
Conclusion: The effects of rifampin on the pharmacokinetics of 
gliclazide suggest that rifampin induced the CYP2C9-catalyzed me- 
tabolism of gliclazide. Concomitant use of rifampin with gliclazide 
can lead to a considerably reduced glucose-lowering effect of glicla- 
zide. 
PDII-A-4 
EVALUATION OF THE PHARMACODYNAMIC AND PHAR- 
MACOKINETIC INTERACTION BETWEEN PAGOCLONE AND 
ETHANOL. G. M. Halg, PharmD, B. Giordani, PhD, E. J. Randi- 
nitis, PhD, D. Y. Mitchell, PhD, Pfizer Global Research and Devel- 
opment, The University of Michigan, Ann Arbor, MI. 
Purpose Pagoclone, a partial GABA A receptor agonist, is being 
developed for treatment of anxiety disorders. This study determined 
the pharmacokinetic (PK) and pharmacodynamic (PD) interaction 
between ethanol (EtOH) and pagoclone. Methods Study design was 
a double-blind, 4-way crossover in 16 healthy women aged 25-54. 
Pagoclone 0.6mg BID or placebo was administered for 5 days. After 
the last pagoclone dose, EtOH 0.7gm/kg or placebo-equivalent EtOH 
(0.4%) was administered. Blood collections for EtOH, pagoclone, 
and PD0302772 (active metabolite) assays, and neuropsychometric 
testing were conducted serially. Results The incidence of CNS and 
GI adverse vents was high, and similar, among subjects receiving 
EtOH and EtOH/pagoclone. Cmax for EtOH alone was 1.2 mg/mL, 
and EtOH with pagoclone was 1.0 mg/mL, indicating intoxicating 
EtOH plasma concentrations. EtOH, pagoclone and PD0302772 
Cmax and AUC met the standard bioequivalence riteria. Generally, 
the treatment rank order of neuropsychometric performance (worst to 
best) was: pagoclone/EtOH>EtOH>>pagoclone>placebo. Pago- 
clone did not express ynergistic effects with EtOH. Pagoclone had 
additive ffects to EtOH in motor screening and in part of a memory 
test. Conclusion No PK or synergistic PD interaction was observed 
between pagoclone and EtOH. Pagoclone exhibited few additive 
effects. However, since individual responses toCNS medications and 
EtOH may vary, patients hould be cautioned about combining EtOH 
and pagoclone. 
PDII-A-5 
EFFECTS OF AMITRIPTYLINE, GABAPENTIN, AND CAR- 
BAMAZEPINE ON MORPHINE-INDUCED RESPIRATORY DE- 
PRESSION IN RABBITS. Eran Kozer, MD, Zina Levichek, MD, 
Noriko Hoshino, MD, Bushan Kapur, PhD, John Leombruno, Gideon 
Koren, MD, Shinya Ito, MD. Division of Clinical Pharmacology and 
Toxicology, The Hospital for Sick Children, Toronto, Ontario, Can- 
ada. 
Although opioids remain the most eftective treatment for severe 
pain, tricyclics and anticonvulsants have been proven useful for 
chronic neuropathic pain. However, data on the drug interactions of 
these drugs and opioids are limited. This study was undertaken to 
characterize effects of chronic use of gabapentin, amitriptylin, and 
carbamazepine on respiratory depression i duced by morphine. 
Methods: Five groups of rabbits received for 5 days saline (Group 
1), amitriptyline 7mg/kg bid (Group 2), carbamazepine 100 mg/kg 
bid (Group 3), or gabapentin 25mg/kg bid (Group 4). Group 5 
received the thiee drugs concurrently. On day 5 morphine 5mg&g 
was given intravenously. Respiratory parameters including arterial 
PCO 2 and morphine serum concentrations were measured repeatedly. 
Results: PaCO2 was higher (p<0.05) throughout the study period 
in Groups 2 and 5. Peak PaCO2 in Group 2 (59-+2mmHg), and Group 
5 (57 -+ l mmHg) were significantly (p<0.001 and p 0.007) higher 
than in Group l(49_+6mmHg). The area under the PaCO2 versus time 
curve was significantly higher in Groups 2, 5 (p<0.00t) and 4 
(p<0.05) than in Groupl. There were no significant differences 
between the groups in morphine serum concentrations. 
Conclusions: Amitriptyline, and gabapentin potentate morphine- 
induced respiratory depression without changing the serum concen- 
trations. Morphine doses need to be reduced if the patient is also 
receiving amitriptylin and/or gabapentine. 
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CYP3A AND P-GLYCOPROTE1N INDUCTION WITH ST. 
JOHN'S WORT IN HEALTHY VOLUNTEERS OF SELECTED 
ETHNIC POPULATIONS. R. Xie, PhD, L. Tan, MD, E. C. Polasek, 
MD, C. Hong, M. Teillol-Foo, MD, T. Gordi, PhD, A. Sharma, PhD, 
E. J. Antal, PhD, Pharmacia, Singapore. 
The inducibilities of CYP3A and P-glycoprotein (Pgp) by St. 
John's Wort (SJW) in six ethnic groups (White, Black, Hispanic, 
Chinese, Indian, and Malay) were investigated. Thirty healthy sub- 
jects (5/gToup) received single dose of fexofenadine (60mg), mida- 
zolam oral (5rag) and IV (2mg, at 6hi" after oral dose) on Dayl and 
Dayl l .  SJW (300mg) was given three times a day on Day2 through 
Dayl l .  Pharmacokinetic (PK) parameters on Dayl (baseline) and 
Dayl 1 (with SJW) of midazolam and fexofenadine were determined 
by non-compat'tment a alysis. Oral clearances (CLpo) of fexofena- 
dine from all subjects were 77_+34 L/h on Dayl and 132+64 L/h on 
Dayl l .  Day 11 CLpo was significantly different from Dayl 
(p<0.001), but no significant differences were detected between 
ethnic groups. The terminal half-lives on Dayl and Dayl l  were 
similar. 
The absolute bioavailability (F), hepatic (FH), and intestinal (FG) 
availabilities of midazolam on Dayl were 0.20_+0.04, 0.73-+0.08 and 
0.28_+0.06, respectively. On Dayt 1, F, FH and FG were 0.t 1 _+0.04, 
0.59-+0.09 and 0.19-+0.06, respectively. The systemic learance (CL) 
of midazolam were 16_+ 5 L/h (Day I ) and 25 _+ 5 L/h (Day 11). The I~ 
and CL on Dayl 1 were significantly different from Dayl (p<0.001), 
but the parameter ratios (Day i l/Day 1) were similar between ethnic 
groups. In conclusion, SJW induces CYP 3A4 and intestinal Pgp and 
intestinal CYP 3A4 was induced to greater extent han that in liver. 
Inducibilities between ethnic groups appeared similar. 
